April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Targeting LOXL2 With An Inhibitory Monoclonal Antibody (AB0023): New Therapeutic Approach For Ocular Diseases Associated With Fibrosis
Author Affiliations & Notes
  • Tine Van Bergen
    Lab of Ophthalmology,
    KU Leuven, Leuven, Belgium
  • Sara Van de Veire
    Lab of Ophthalmology,
    KU Leuven, Leuven, Belgium
  • Evelien Vandewalle
    Lab of Ophthalmology,
    KU Leuven, Leuven, Belgium
  • Lieve Moons
    Department of Biology,
    KU Leuven, Leuven, Belgium
  • Jean Herman
    Interdepartementaal Valorisatie Platform (IVAP),
    KU Leuven, Leuven, Belgium
  • Victoria Smith
    Arresto Biosciences, Palo Alto, California
  • Ingeborg Stalmans
    Lab of Ophthalmology,
    KU Leuven, Leuven, Belgium
  • Footnotes
    Commercial Relationships  Tine Van Bergen, US 20100203062A1 (P); Sara Van de Veire, None; Evelien Vandewalle, None; Lieve Moons, None; Jean Herman, None; Victoria Smith, Arresto Biosciences (I), US2010/020362A1 (P); Ingeborg Stalmans, Arresto Biosciences (F), US20100203062A1 (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4547. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tine Van Bergen, Sara Van de Veire, Evelien Vandewalle, Lieve Moons, Jean Herman, Victoria Smith, Ingeborg Stalmans; Targeting LOXL2 With An Inhibitory Monoclonal Antibody (AB0023): New Therapeutic Approach For Ocular Diseases Associated With Fibrosis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4547. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Lysyl oxidase-like protein 2 (LOXL2) is known to be involved in the crosslinking of collagen and elastin, and also to play a role in "aberrant" wound healing or fibrosis. We have previously shown that LOXL2 was upregulated in a rabbit model of glaucoma surgery and a mouse model of choroidal neovascularization (CNV). The aim of this study was to investigate the efficacy of a monoclonal antibody against LOXL2 (AB0023) in both preclinical models.

Methods: : Treatment with AB0023 (study eye) and vehicle (control eye) was initiated in rabbits (n=6) on day 0 after trabeculectomy by giving an intracameral injection (0.6 mg) and a subconjunctival (SC) injection (0.3 mg). Thereafter, repeated injections were given twice a week SC (0.3 mg) until 30 days after the surgery. In C75Bl/6 mice, CNV was induced by placing 3 laser spots. The anti-LOXL2 antibody (n =10) and vehicle (n=10) were administered every other day intraperitoneally (0.75mg) until day 35. Treatment outcome was studied by clinical investigation (IOP, bleb area and bleb survival) and by analysis of angiogenesis (CD31), inflammation (CD45) and collagen deposition (Sirius Red).

Results: : In the trabeculectomy model, treatment using the anti-LOXL2 antibody significantly improved surgical outcome by increasing bleb area (p<0.001) and bleb survival (p=0.0005) compared to control. Analyses of the different immunohistological stainings on day 30 showed a significant reduction in angiogenesis (47%; p=0.01), inflammation (34%; p=0.0003) and fibrosis (16%; p=0.01) compared to control. In the CNV-model, AB0023 was also able to significantly reduce angiogenesis (43%; p=0.0003), inflammation (34%; p=0.0005) and fibrosis (26%; p=0.006) on day 35 compared to vehicle treated mice.

Conclusions: : Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) is efficacious in reducing angiogenesis, inflammation and fibrosis in a rabbit model of glaucoma surgery, and a murine model of CNV. These results render LOXL2 an appealing target for ocular fibrotic diseases, and point to the potential therapeutic benefits of the monoclonal antibody AB0023 in these diseases.

Keywords: wound healing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×